Back to Newsroom

Cempra Presents Late-Breaker on Solithromycin’s Anti NASH Effects in an Animal Model at DDW 2014

CHAPEL HILL, N.C., May 6, 2014 (GLOBE NEWSWIRE) — Cempra, Inc., (Nasdaq:CEMP) today announced a late-breaker presentation demonstrating that solithromycin significantly reduced ballooning degeneration and inflammation which are histological signs of non-alcoholic steatohepatitis (NASH) in an animal model at Digestive Disease Week (DDW) in Chicago. The abstract titled, “Anti-NASH Effects of Solithromycin in NASH-HCC Mouse Model,” will be presented at 9:15 a.m. CDT, Tuesday, May 6 , in Room S015A at McCormick Place in Chicago.

Click here to read more